ArticleCells2022

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an

Shigetoshi Nishihara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.